Pfizer Inc. $PFE Shares Purchased by First Horizon Corp

Posted by George Bondi on Jul 10th, 2026

First Horizon Corp lifted its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 59.6% in the first quarter, Holdings Channel.com reports. The institutional investor owned 329,278 shares of the biopharmaceutical company’s stock after purchasing an additional 122,904 shares during the quarter. First Horizon Corp’s holdings in Pfizer were worth $9,246,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Horizon Financial Services LLC grew its holdings in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new position in Pfizer during the fourth quarter worth about $26,000. YANKCOM Partnership acquired a new position in shares of Pfizer in the 4th quarter worth approximately $28,000. HFM Investment Advisors LLC increased its holdings in shares of Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares in the last quarter. Finally, Evolution Wealth Management Inc. raised its position in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer shares benefited as AstraZeneca’s failed Phase 3 trial in a rare heart disease pushed investors toward rival drugmakers, including PFE. Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
Positive Sentiment: Pfizer’s oncology franchise got some attention after reports suggesting recent FDA action on IBRANCE could improve the investment case for the company’s cancer portfolio. Did FDA’s IBRANCE Maintenance Approval Just Shift Pfizer’s (PFE) Oncology-Focused Investment Narrative?
Positive Sentiment: Pfizer also highlighted ongoing pipeline work, including a Phase 1 bioavailability study and its MUST multiple myeloma study, reinforcing the company’s longer-term R&D pipeline narrative. Pfizer Refines Early-Stage Drug Formulations With New Phase 1 Bioavailability Study Pfizer’s MUST Study Offers Fresh Insight Into Tough‑to‑Treat Multiple Myeloma
Neutral Sentiment: J.P. Morgan lowered its price target on Pfizer and kept a Neutral rating, which signals continued caution even though the firm still sees some upside from current levels. Pfizer (PFE) Receives a Hold from J.P. Morgan
Neutral Sentiment: Additional headlines around Pfizer’s dividend appeal, valuation, and analyst commentary are likely reinforcing investor debate, but they do not point to a major fundamental shift by themselves. Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Negative Sentiment: Jim Cramer declined to recommend Pfizer despite its high dividend yield, reflecting ongoing skepticism about the stock’s near-term appeal. ‘It Kills Me to Say That’: Cramer Won’t Recommend Pfizer, Even With Its 7% Dividend

Pfizer Stock Up 0.7%

Shares of PFE stock opened at $24.22 on Friday. The stock has a fifty day moving average price of $25.41 and a 200 day moving average price of $26.20. The stock has a market cap of $138.02 billion, a P/E ratio of 18.49 and a beta of 0.35. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE – Get Free Report) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is currently 131.30%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. CICC Research started coverage on shares of Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target on the stock. Guggenheim raised their price target on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Citigroup upped their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a report on Tuesday, June 9th. Finally, HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and cut their target price for the stock from $32.00 to $28.00 in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average target price of $28.56.

Get Our Latest Research Report on Pfizer

About Pfizer

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.